Phenotype
|
Conditions
|
Figures
|
acute inflammatory response increased occurrence, abnormal
|
chemical treatment: copper(II) sulfate
|
Fig. 3
from Gallardo et al., 2015
|
caudal fin neutrophil amount, ameliorated
|
transection: caudal fin, chemical treatment by environment: AH23848, chemical treatment by environment: prostaglandin E2
|
Fig. 4
from Loynes et al., 2018
|
caudal fin neutrophil apoptotic, abnormal
|
amputation: caudal fin
|
Figure 3
from Bernut et al., 2020
|
caudal fin neutrophil decreased amount, abnormal
|
transection: caudal fin, chemical treatment by environment: prostaglandin E2
|
Fig. 3
from Loynes et al., 2018
|
caudal fin neutrophil decreased amount, abnormal
|
transection: caudal fin, chemical treatment by injection: lipoxin A4
|
Fig. 6
from Loynes et al., 2018
|
caudal fin neutrophil increased amount, abnormal
|
chemical treatment by injection: N-formyl-L-methionyl-L-leucyl-L-phenylalanine, amputation: caudal fin
|
Figure 1
from Bernut et al., 2020
|
caudal fin neutrophil increased amount, abnormal
|
amputation: caudal fin
|
Figure 2
from Bernut et al., 2020
|
caudal fin neutrophil increased amount, abnormal
|
transection: caudal fin, chemical treatment by injection: EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor
|
Fig. 5
from Loynes et al., 2018
|
caudal fin neutrophil increased amount, abnormal
|
transection: caudal fin, chemical treatment by injection: EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor, chemical treatment by environment: prostaglandin E2
|
Fig. 5
from Loynes et al., 2018
|
caudal fin neutrophil increased amount, abnormal
|
transection: caudal fin, chemical treatment by environment: AH23848
|
Fig. 4
from Loynes et al., 2018
|
caudal fin neutrophil increased amount, ameliorated
|
chemical treatment by environment: dibenziodolium chloride, amputation: caudal fin
|
Figure 2
from Bernut et al., 2020
|
caudal fin neutrophil increased amount, exacerbated
|
chemical treatment by environment: hydrogen peroxide, amputation: caudal fin
|
Figure 2
from Bernut et al., 2020
|
caudal fin regenerating fin decreased accumulation neutrophil, abnormal
|
transection: caudal fin, chemical treatment: tyrphostin AG 825
|
Figure 6
from Rahman et al., 2019
|
caudal fin regenerating fin decreased accumulation neutrophil, abnormal
|
transection: caudal fin, chemical treatment: CP-724714
|
Figure 6
from Rahman et al., 2019
|
caudal hematopoietic tissue neoplasm increased amount, abnormal
|
cancer xenotransplantation
|
Fig. 3
from Kiener et al., 2019
|
caudal hematopoietic tissue neutrophil apoptotic process increased occurrence, abnormal
|
chemical treatment: tyrphostin AG 825
|
Figure 6
from Rahman et al., 2019
|
caudal hematopoietic tissue neutrophil apoptotic process occurrence, normal
|
chemical treatment: CP-724714
|
Figure 6
from Rahman et al., 2019
|
cysteine-type endopeptidase activity involved in apoptotic process decreased occurrence, abnormal
|
chemical treatment by environment: EC 3.4.22.36 (caspase-1) inhibitor, bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium
|
Fig. 4
from Tyrkalska et al., 2019
|
cysteine-type endopeptidase activity involved in apoptotic process decreased occurrence, abnormal
|
chemical treatment by environment: EC 3.4.22.36 (caspase-1) inhibitor
|
Fig. 1,
Fig. 4
from Tyrkalska et al., 2019
|
cysteine-type endopeptidase activity involved in apoptotic process increased occurrence, abnormal
|
bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium
|
Fig. 4
from Tyrkalska et al., 2019
|
gall bladder morphology, abnormal
|
chemical treatment: biliatresone
|
Fig. 3
from Lorent et al., 2015
|
gill neutrophil amount, ameliorated
|
chemical treatment: environmental contaminant
|
Fig. 4
from Progatzky et al., 2016
|
gill neutrophil decreased amount, abnormal
|
chemical treatment: environmental contaminant
|
Fig. 3,
Fig. 4
from Progatzky et al., 2016
|
head macrophage increased amount, abnormal
|
chemical treatment by environment: pentetrazol
|
Fig. 6
from Jin et al., 2018
|
head neutrophil increased amount, abnormal
|
chemical treatment by environment: pentetrazol
|
Fig. 6
from Jin et al., 2018
|
heart leukocyte activation increased occurrence, abnormal
|
chemical treatment by environment: isoprenaline
|
Fig. 6
from Kossack et al., 2017
|
heart neutrophil increased amount, abnormal
|
chemical treatment by environment: isoprenaline
|
Fig. 6
from Kossack et al., 2017
|
hindbrain macrophage decreased amount, abnormal
|
fungal treatment by injection: Mucor circinelloides, chemical treatment by environment: dexamethasone
|
Fig. 2
from Inglesfield et al., 2018
|
hindbrain neutrophil decreased amount, abnormal
|
fungal treatment by injection: Mucor circinelloides, chemical treatment by environment: dexamethasone
|
Fig. 2
from Inglesfield et al., 2018
|
hindbrain neutrophil increased amount, abnormal
|
fungal treatment by injection: Mucor circinelloides
|
Fig. 2
from Voelz et al., 2015
|
inflammatory response increased occurrence, abnormal
|
chemical treatment by injection: lipopolysaccharide
|
Fig. 1
from Luo et al., 2019
|
inflammatory response to wounding process quality, abnormal
|
transection: caudal fin, chemical treatment: CP-724714
|
Figure 6
from Rahman et al., 2019
|
inflammatory response to wounding process quality, abnormal
|
transection: caudal fin, chemical treatment: tyrphostin AG 825
|
Figure 6
from Rahman et al., 2019
|
intestine anatomical region has extra parts of type neutrophil, abnormal
|
bacterial treatment by diet: Escherichia coli O157:H7
|
Fig. 3
from Stones et al., 2017
|
intestine neutrophil amount, ameliorated
|
chemical treatment by diet: glycoprotein, protein content
|
Fig. 1
from Ulloa et al., 2016
|
intestine neutrophil amount, ameliorated
|
chemical treatment by environment: cabergoline, chemical treatment by environment: dextran sulfate
|
Fig. 2
from Oehlers et al., 2017
|
intestine neutrophil amount, ameliorated
|
chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid, chemical treatment by environment: cabergoline
|
Fig. 2
from Oehlers et al., 2017
|
intestine neutrophil amount, ameliorated
|
chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid, chemical treatment by environment: sincalide
|
Fig. 3
from Oehlers et al., 2017
|
intestine neutrophil decreased amount, abnormal
|
germ free
|
Fig. 1
from Koch et al., 2018
|
intestine neutrophil increased amount, abnormal
|
chemical treatment by environment: dextran sulfate
|
Fig. 2,
Fig. 3
from Oehlers et al., 2017
|
intestine neutrophil increased amount, abnormal
|
chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid
|
Fig. 1,
Fig. 2,
Fig. 3
from Oehlers et al., 2017
|
intestine neutrophil increased amount, abnormal
|
chemical treatment by diet: glycoprotein, protein content
|
Fig. 1
from Ulloa et al., 2016
|
intestine neutrophil increased amount, abnormal
|
chemical treatment by environment: dextran sulfate, chemical treatment by environment: sincalide
|
Fig. 3
from Oehlers et al., 2017
|
intestine neutrophil increased amount, exacerbated
|
chemical treatment by environment: haloperidol, chemical treatment by environment: dextran sulfate
|
Fig. 2
from Oehlers et al., 2017
|
intestine neutrophil increased amount, exacerbated
|
chemical treatment by environment: lorglumide
|
Fig. 3
from Oehlers et al., 2017
|
intestine neutrophil increased amount, exacerbated
|
chemical treatment by environment: dextran sulfate, chemical treatment by environment: devazepide
|
Fig. 3
from Oehlers et al., 2017
|
intestine neutrophil increased amount, exacerbated
|
chemical treatment by environment: devazepide, chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid
|
Fig. 3
from Oehlers et al., 2017
|
intestine neutrophil increased amount, exacerbated
|
chemical treatment by environment: lorglumide, chemical treatment by environment: dextran sulfate, chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid
|
Fig. 3
from Oehlers et al., 2017
|
intestine neutrophil infiltrative, abnormal
|
chemical treatment by injection: 4-(ethoxymethylene)-2-phenyloxazol-5-one
|
Fig. 4
from Brugman et al., 2009
|
leukocyte il1b expression amount, ameliorated
|
transection: caudal fin, chemical treatment by environment: purinergic receptor P2X antagonist
|
Fig. 4
from Ogryzko et al., 2014
|
leukocyte il1b expression amount, ameliorated
|
transection: caudal fin, chemical treatment by environment: EC 3.4.22.36 (caspase-1) inhibitor
|
Fig. 4
from Ogryzko et al., 2014
|
leukocyte ptgs2b expression increased amount, abnormal
|
transection: caudal fin, chemical treatment by environment: purinergic receptor P2X antagonist
|
Fig. 4
from Ogryzko et al., 2014
|
leukocyte ptgs2b expression increased amount, abnormal
|
transection: caudal fin, chemical treatment by environment: EC 3.4.22.36 (caspase-1) inhibitor
|
Fig. 4
from Ogryzko et al., 2014
|
leukocyte il1b expression increased amount, abnormal
|
transection: caudal fin
|
Fig. 4
from Ogryzko et al., 2014
|
leukocyte cxcl8a expression increased amount, abnormal
|
transection: caudal fin
|
Fig. 4
from Ogryzko et al., 2014
|
leukocyte ptgs2b expression increased amount, abnormal
|
transection: caudal fin
|
Fig. 4
from Ogryzko et al., 2014
|
leukocyte cxcl8a expression increased amount, abnormal
|
transection: caudal fin, chemical treatment by environment: EC 3.4.22.36 (caspase-1) inhibitor
|
Fig. 4
from Ogryzko et al., 2014
|
leukocyte cxcl8a expression increased amount, abnormal
|
transection: caudal fin, chemical treatment by environment: purinergic receptor P2X antagonist
|
Fig. 4
from Ogryzko et al., 2014
|
leukocyte protein nitrosylation increased process quality, abnormal
|
bacterial treatment
|
Fig. 3 ,
Fig. 7
from Elks et al., 2013
|
leukocyte migration involved in inflammatory response process quality, abnormal
|
physical alteration: anatomical structure, chemical treatment: pharmaceutical
|
Fig. 3,
Fig. 5,
Fig. 6
from Burgon et al., 2014
|
leukocyte migration involved in inflammatory response process quality, abnormal
|
physical alteration: anatomical structure, chemical treatment: pharmaceutical
|
Fig. 6
from Burgon et al., 2014
|
leukocyte migration involved in inflammatory response process quality, abnormal
|
physical alteration: caudal fin, chemical treatment: pharmaceutical
|
Fig. 7
from de Oliveira et al., 2013
|
macrophage accumulation caudal fin, abnormal
|
chemical treatment by environment: lipopolysaccharide
|
Fig. 4
from Philip et al., 2017
|
macrophage accumulation liver and biliary system, abnormal
|
chemical treatment: biliatresone
|
Fig. 3
from Lorent et al., 2015
|
macrophage decreased amount, abnormal
|
viral treatment: Sprivirus cyprinus
|
Fig. 6
from Varela et al., 2014
|
neutrophil accumulation swim bladder, abnormal
|
fungal treatment by injection: Mucor circinelloides
|
Fig. 5
from Voelz et al., 2015
|
neutrophil accumulation liver and biliary system, abnormal
|
chemical treatment: biliatresone
|
Fig. 3
from Lorent et al., 2015
|
neutrophil amount, normal
|
bacterial treatment by exposure to environment: Pseudomonas aeruginosa
|
Fig. 1
from DÃaz-Pascual et al., 2017
|
neutrophil decreased amount, abnormal
|
chemical treatment by environment: EC 3.4.22.36 (caspase-1) inhibitor
|
Fig. 1,
Fig. 4
from Tyrkalska et al., 2019
|
neutrophil decreased amount, abnormal
|
chemical treatment by environment: EC 3.4.22.36 (caspase-1) inhibitor, bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium
|
Fig. 4
from Tyrkalska et al., 2019
|
neutrophil decreased amount, abnormal
|
bacterial treatment by injection: Burkholderia cenocepacia
|
Fig. 3
from Mesureur et al., 2017
|
neutrophil decreased amount, abnormal
|
chemical treatment by environment: sunitinib
|
Fig. 3
from Delasoie et al., 2020
|
neutrophil decreased amount, abnormal
|
chemical treatment by environment: doxorubicin
|
Fig. 3
from Delasoie et al., 2020
|
neutrophil decreased speed, abnormal
|
physical alteration: anatomical structure, chemical treatment: pharmaceutical
|
Fig. 6
from Burgon et al., 2014
|
neutrophil decreased speed, abnormal
|
physical alteration: anatomical structure, chemical treatment: pharmaceutical
|
Fig. 4,
Fig. 6
from Burgon et al., 2014
|
neutrophil increased accumulation caudal fin, abnormal
|
transection: caudal fin
|
Fig. 1
from Dapueto et al., 2020
|
neutrophil increased amount, abnormal
|
chemical treatment by injection: 4-(ethoxymethylene)-2-phenyloxazol-5-one
|
Fig. 4
from Brugman et al., 2009
|
neutrophil increased amount, abnormal
|
chemical treatment by injection: lipopolysaccharide
|
Fig. 1
from Luo et al., 2019
|
neutrophil increased amount, abnormal
|
bacterial treatment by injection: Burkholderia stabilis
|
Fig. 3
from Mesureur et al., 2017
|
neutrophil increased amount, abnormal
|
fungal treatment by injection: Mucor circinelloides
|
Fig. 1
from Inglesfield et al., 2018
|
neutrophil il1b expression increased amount, abnormal
|
bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium
|
Fig. 1
from Tyrkalska et al., 2016
|
neutrophil increased amount, abnormal
|
bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium
|
Fig. 4
from Tyrkalska et al., 2019
|
neutrophil increased amount, abnormal
|
bacterial treatment by injection: Burkholderia cenocepacia
|
Fig. 7
from Mesureur et al., 2017
|
neutrophil caiap expression increased amount, abnormal
|
bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium
|
Fig. 3
from Tyrkalska et al., 2017
|
neutrophil increased amount, abnormal
|
bacterial treatment by injection: Escherichia coli DH5[alpha]
|
Fig. 3
from DÃaz-Pascual et al., 2017
|
neutrophil increased amount, abnormal
|
bacterial treatment by injection: Pseudomonas aeruginosa
|
Fig. 3
from DÃaz-Pascual et al., 2017
|
neutrophil increased amount, abnormal
|
chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid
|
Fig. 1
from Oehlers et al., 2017
|
neutrophil mislocalised, abnormal
|
standard conditions
|
Fig. Sup. 1
from Lu et al., 2020
|
neutrophil normal amount, normal
|
chemical treatment: pharmaceutical
|
Fig. 3
from Herbst et al., 2015
|
neutrophil shape, abnormal
|
standard conditions
|
Fig. Sup. 1
from Lu et al., 2020
|
neutrophil apoptotic process increased process quality, abnormal
|
physical alteration: anatomical structure, chemical treatment: pharmaceutical
|
Fig. 3
from Burgon et al., 2014
|
neutrophil inflammatory response to wounding decreased duration, abnormal
|
transection: caudal fin, chemical treatment by environment: prostaglandin E2
|
Fig. 3
from Loynes et al., 2018
|
neutrophil inflammatory response to wounding decreased duration, abnormal
|
transection: caudal fin, chemical treatment by injection: lipoxin A4
|
Fig. 6
from Loynes et al., 2018
|
neutrophil inflammatory response to wounding increased duration, abnormal
|
transection: caudal fin, chemical treatment by injection: EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor
|
Fig. 5
from Loynes et al., 2018
|
neutrophil inflammatory response to wounding increased duration, abnormal
|
transection: caudal fin, chemical treatment by injection: EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor, chemical treatment by environment: prostaglandin E2
|
Fig. 5
from Loynes et al., 2018
|
neutrophil apoptotic process increased occurrence, abnormal
|
transection: caudal fin, chemical treatment by injection: 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide
|
Fig. 3
from Hoodless et al., 2016
|
neutrophil apoptotic process occurrence, normal
|
transection: caudal fin, chemical treatment by injection: 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide
|
Fig. 3
from Hoodless et al., 2016
|
neutrophil chemotaxis decreased occurrence, abnormal
|
transection: caudal fin, chemical treatment by environment: purinergic receptor P2X antagonist
|
Fig. 2
from Ogryzko et al., 2014
|
neutrophil chemotaxis decreased occurrence, abnormal
|
transection: caudal fin, chemical treatment by environment: EC 3.4.22.36 (caspase-1) inhibitor
|
Fig. 2
from Ogryzko et al., 2014
|
neutrophil chemotaxis decreased occurrence, abnormal
|
chemical treatment by environment: SB220025, amputation: caudal fin
|
Fig. 4
from de Oliveira et al., 2015
|
neutrophil chemotaxis decreased occurrence, abnormal
|
chemical treatment by environment: anthra[1,9-cd]pyrazol-6(2H)-one, amputation: caudal fin
|
Fig. 4
from de Oliveira et al., 2015
|
neutrophil chemotaxis decreased occurrence, abnormal
|
chemical treatment by environment: 2-(2-amino-3-methoxyphenyl)chromen-4-one, amputation: caudal fin
|
Fig. 4
from de Oliveira et al., 2015
|
neutrophil chemotaxis decreased occurrence, abnormal
|
chemical treatment by environment: wortmannin, amputation: caudal fin
|
Fig. 4
from de Oliveira et al., 2015
|
neutrophil chemotaxis decreased occurrence, abnormal
|
chemical treatment by environment: PP2, amputation: caudal fin
|
Fig. 4
from de Oliveira et al., 2015
|
neutrophil chemotaxis decreased occurrence, abnormal
|
chemical treatment by environment: inhibitor, amputation: caudal fin
|
Fig. 1
from Ke et al., 2017
|
neutrophil chemotaxis decreased process quality, abnormal
|
amputation: caudal fin, chemical treatment: dibenziodolium chloride
|
Fig. 2
from de Oliveira et al., 2014
|
neutrophil chemotaxis decreased process quality, abnormal
|
chemical treatment by environment: inhibitor, amputation: caudal fin
|
Fig. 1
from Ke et al., 2017
|
neutrophil chemotaxis increased occurrence, abnormal
|
bacterial treatment by diet: Escherichia coli O157:H7
|
Fig. 3
from Stones et al., 2017
|
neutrophil chemotaxis increased occurrence, abnormal
|
bacterial treatment by injection: Pseudomonas aeruginosa
|
Fig. 3
from DÃaz-Pascual et al., 2017
|
neutrophil chemotaxis increased occurrence, abnormal
|
bacterial treatment by injection: Escherichia coli DH5[alpha]
|
Fig. 3
from DÃaz-Pascual et al., 2017
|
neutrophil migration decreased occurrence, abnormal
|
chemical treatment by environment: inhibitor, amputation: caudal fin
|
Fig. 1
from Ke et al., 2017
|
neutrophil migration decreased process quality, abnormal
|
chemical treatment by environment: inhibitor, amputation: caudal fin
|
Fig. 1
from Ke et al., 2017
|
neutrophil migration decreased process quality, abnormal
|
transection: caudal fin, chemical treatment by environment: isopimpinellin
|
Fig. 2
from Robertson et al., 2016
|
neutrophil migration process quality, abnormal
|
chemical treatment by environment: inhibitor, amputation: caudal fin
|
Fig. 1
from Ke et al., 2017
|
neutrophil migration process quality, abnormal
|
physical alteration: anatomical structure, chemical treatment: pharmaceutical
|
Fig. 3,
Fig. 4,
Fig. 5,
Fig. 6
from Burgon et al., 2014
|
neutrophil migration process quality, abnormal
|
physical alteration: anatomical structure, chemical treatment: pharmaceutical
|
Fig. 6
from Burgon et al., 2014
|
neutrophil migration process quality, normal
|
bacterial treatment by exposure to environment: Pseudomonas aeruginosa
|
Fig. 1
from DÃaz-Pascual et al., 2017
|
neutrophil-mediated killing of fungus process quality, normal
|
fungal treatment by injection: Candida albicans
|
Fig. 2
from Brothers et al., 2011
|
notochord neutrophil increased amount, abnormal
|
bacterial treatment by injection: Escherichia coli K-12
|
Fig. 7
from Nguyen-Chi et al., 2014
|
phagocytosis process quality, normal
|
fungal treatment by injection: Candida albicans
|
Fig. 2
from Brothers et al., 2011
|
regenerating fin neutrophil decreased amount, abnormal
|
transection: caudal fin, chemical treatment by injection: 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide
|
Fig. 2 ,
Fig. 7
from Hoodless et al., 2016
|
regenerating fin neutrophil decreased amount, abnormal
|
transection: caudal fin, chemical treatment by environment: alvocidib
|
Fig. 2
from Hoodless et al., 2016
|
regenerating fin neutrophil apoptotic process increased occurrence, abnormal
|
transection: caudal fin, chemical treatment: tyrphostin AG 825
|
Figure 6
from Rahman et al., 2019
|
regenerating fin neutrophil apoptotic process increased occurrence, abnormal
|
transection: caudal fin, chemical treatment: CP-724714
|
Figure 6
from Rahman et al., 2019
|
regenerating fin neutrophil chemotaxis occurrence, normal
|
transection: caudal fin, chemical treatment by injection: 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide
|
Fig. 2
from Hoodless et al., 2016
|
regenerating fin neutrophil chemotaxis occurrence, normal
|
transection: caudal fin, chemical treatment by environment: alvocidib
|
Fig. 2
from Hoodless et al., 2016
|
regeneration epithelium neutrophil decreased amount, abnormal
|
transection: caudal fin
|
Fig. 6
from Robertson et al., 2016
|
regeneration epithelium neutrophil decreased amount, abnormal
|
transection: caudal fin, chemical treatment by injection: nedocromil
|
Fig. 6
from Robertson et al., 2016
|
regeneration epithelium neutrophil decreased amount, abnormal
|
transection: caudal fin, chemical treatment by environment: isopimpinellin
|
Fig. 2 ,
Fig. 3
from Robertson et al., 2016
|
skeletal muscle neutrophil increased amount, abnormal
|
viral treatment by injection: unidentified influenza virus
|
Fig. 4
from Goody et al., 2017
|
skeletal muscle cell degenerate, abnormal
|
viral treatment by injection: unidentified influenza virus
|
Fig. 4
from Goody et al., 2017
|
skeletal muscle cell detached from skeletal muscle cell, abnormal
|
viral treatment by injection: unidentified influenza virus
|
Fig. 4
from Goody et al., 2017
|
swim bladder neutrophil decreased amount, abnormal
|
chemical treatment by environment: epidermal growth factor receptor antagonist, fungal treatment by injection: Candida albicans
|
Fig. 3
from Ho et al., 2019
|
trunk neutrophil increased amount, abnormal
|
chemical treatment by environment: 2,4,5-trinitrobenzenesulfonic acid
|
Fig. 1
from Oehlers et al., 2017
|
ventral fin fold neutrophil localized, abnormal
|
transection: ventral fin fold
|
Fig. 3
from Coombs et al., 2019
|
ventral fin fold neutrophil migration increased occurrence, abnormal
|
transection: ventral fin fold
|
Fig. 3
from Coombs et al., 2019
|
whole organism ifng1 expression amount, ameliorated
|
chemical treatment by injection: lipopolysaccharide, chemical treatment by environment: ononin
|
Fig. 4
from Luo et al., 2019
|
whole organism ifng1 expression amount, ameliorated
|
chemical treatment by injection: lipopolysaccharide, chemical treatment by environment: indometacin
|
Fig. 4
from Luo et al., 2019
|
whole organism ifng1 expression amount, ameliorated
|
chemical treatment by injection: lipopolysaccharide, chemical treatment by environment: formononetin
|
Fig. 4
from Luo et al., 2019
|
whole organism myd88 expression amount, ameliorated
|
chemical treatment by injection: lipopolysaccharide, chemical treatment by environment: indometacin
|
Fig. 4
from Luo et al., 2019
|
whole organism myd88 expression amount, ameliorated
|
chemical treatment by injection: lipopolysaccharide, chemical treatment by environment: ononin
|
Fig. 4
from Luo et al., 2019
|
whole organism myd88 expression amount, ameliorated
|
chemical treatment by injection: lipopolysaccharide, chemical treatment by environment: formononetin
|
Fig. 4
from Luo et al., 2019
|
whole organism tnfa expression amount, ameliorated
|
chemical treatment by injection: lipopolysaccharide, chemical treatment by environment: ononin
|
Fig. 4
from Luo et al., 2019
|
whole organism tnfa expression amount, ameliorated
|
chemical treatment by injection: lipopolysaccharide, chemical treatment by environment: indometacin
|
Fig. 4
from Luo et al., 2019
|
whole organism tnfa expression amount, ameliorated
|
chemical treatment by injection: lipopolysaccharide, chemical treatment by environment: formononetin
|
Fig. 4
from Luo et al., 2019
|
whole organism il6 expression amount, ameliorated
|
chemical treatment by injection: lipopolysaccharide, chemical treatment by environment: ononin
|
Fig. 4
from Luo et al., 2019
|
whole organism il6 expression amount, ameliorated
|
chemical treatment by injection: lipopolysaccharide, chemical treatment by environment: indometacin
|
Fig. 4
from Luo et al., 2019
|
whole organism il6 expression amount, ameliorated
|
chemical treatment by injection: lipopolysaccharide, chemical treatment by environment: formononetin
|
Fig. 4
from Luo et al., 2019
|
whole organism ticam1 expression amount, ameliorated
|
chemical treatment by injection: lipopolysaccharide, chemical treatment by environment: ononin
|
Fig. 4
from Luo et al., 2019
|
whole organism ticam1 expression amount, ameliorated
|
chemical treatment by injection: lipopolysaccharide, chemical treatment by environment: formononetin
|
Fig. 4
from Luo et al., 2019
|
whole organism ticam1 expression amount, ameliorated
|
chemical treatment by injection: lipopolysaccharide, chemical treatment by environment: indometacin
|
Fig. 4
from Luo et al., 2019
|
whole organism ticam1 expression amount, ameliorated
|
chemical treatment by injection: lipopolysaccharide
|
Fig. 4
from Luo et al., 2019
|
whole organism il1b expression amount, ameliorated
|
chemical treatment by injection: lipopolysaccharide, chemical treatment by environment: formononetin
|
Fig. 4
from Luo et al., 2019
|
whole organism il1b expression amount, ameliorated
|
chemical treatment by injection: lipopolysaccharide, chemical treatment by environment: ononin
|
Fig. 4
from Luo et al., 2019
|
whole organism il1b expression amount, ameliorated
|
chemical treatment by injection: lipopolysaccharide, chemical treatment by environment: indometacin
|
Fig. 4
from Luo et al., 2019
|
whole organism rela expression amount, ameliorated
|
chemical treatment by injection: lipopolysaccharide, chemical treatment by environment: formononetin
|
Fig. 4
from Luo et al., 2019
|
whole organism rela expression amount, ameliorated
|
chemical treatment by injection: lipopolysaccharide, chemical treatment by environment: ononin
|
Fig. 4
from Luo et al., 2019
|
whole organism rela expression amount, ameliorated
|
chemical treatment by injection: lipopolysaccharide, chemical treatment by environment: indometacin
|
Fig. 4
from Luo et al., 2019
|
whole organism mapk14a expression amount, ameliorated
|
chemical treatment by injection: lipopolysaccharide, chemical treatment by environment: indometacin
|
Fig. 4
from Luo et al., 2019
|
whole organism mapk3 expression amount, ameliorated
|
chemical treatment by injection: lipopolysaccharide, chemical treatment by environment: formononetin
|
Fig. 4
from Luo et al., 2019
|
whole organism mapk3 expression amount, ameliorated
|
chemical treatment by injection: lipopolysaccharide, chemical treatment by environment: ononin
|
Fig. 4
from Luo et al., 2019
|
whole organism mapk3 expression amount, ameliorated
|
chemical treatment by injection: lipopolysaccharide, chemical treatment by environment: indometacin
|
Fig. 4
from Luo et al., 2019
|
whole organism nfkbiab expression amount, ameliorated
|
chemical treatment by injection: lipopolysaccharide, chemical treatment by environment: indometacin
|
Fig. 4
from Luo et al., 2019
|
whole organism il10 expression amount, ameliorated
|
chemical treatment by injection: lipopolysaccharide, chemical treatment by environment: formononetin
|
Fig. 4
from Luo et al., 2019
|
whole organism il10 expression amount, ameliorated
|
chemical treatment by injection: lipopolysaccharide, chemical treatment by environment: indometacin
|
Fig. 4
from Luo et al., 2019
|
whole organism nfkbiab expression decreased amount, abnormal
|
chemical treatment by injection: lipopolysaccharide
|
Fig. 4
from Luo et al., 2019
|
whole organism il10 expression decreased amount, abnormal
|
chemical treatment by injection: lipopolysaccharide
|
Fig. 4
from Luo et al., 2019
|
whole organism decreased life span, abnormal
|
fungal treatment by injection: Mucor circinelloides, chemical treatment by environment: dexamethasone
|
Fig. 2
from Inglesfield et al., 2018
|
whole organism decreased life span, abnormal
|
chemical treatment by environment: epidermal growth factor receptor antagonist, fungal treatment by injection: Candida albicans
|
Fig. 3
from Ho et al., 2019
|
whole organism tnfa expression increased amount, abnormal
|
chemical treatment by injection: lipopolysaccharide
|
Fig. 4
from Luo et al., 2019
|
whole organism il6 expression increased amount, abnormal
|
chemical treatment by injection: lipopolysaccharide
|
Fig. 4
from Luo et al., 2019
|
whole organism gbp4 expression increased amount, abnormal
|
bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium
|
Fig. 1
from Tyrkalska et al., 2016
|
whole organism myd88 expression increased amount, abnormal
|
chemical treatment by injection: lipopolysaccharide
|
Fig. 4
from Luo et al., 2019
|
whole organism mapk3 expression increased amount, abnormal
|
chemical treatment by injection: lipopolysaccharide
|
Fig. 4
from Luo et al., 2019
|
whole organism ticam1 expression increased amount, abnormal
|
chemical treatment by injection: lipopolysaccharide
|
Fig. 4
from Luo et al., 2019
|
whole organism ifng1 expression increased amount, abnormal
|
chemical treatment by injection: lipopolysaccharide
|
Fig. 4
from Luo et al., 2019
|
whole organism cxcl8a expression increased amount, abnormal
|
chemical treatment by environment: poly(I:C)
|
Fig. 1
from de Oliveira et al., 2015
|
whole organism cxcl8a expression increased amount, abnormal
|
chemical treatment by environment: double-stranded DNA
|
Fig. 1
from de Oliveira et al., 2015
|
whole organism cxcl8a expression increased amount, abnormal
|
viral treatment by exposure to environment: Sprivirus cyprinus
|
Fig. 1
from de Oliveira et al., 2015
|
whole organism cxcl8a expression increased amount, abnormal
|
bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium
|
Fig. 1
from de Oliveira et al., 2015
|
whole organism rela expression increased amount, abnormal
|
chemical treatment by injection: lipopolysaccharide
|
Fig. 4
from Luo et al., 2019
|
whole organism mapk14a expression increased amount, abnormal
|
chemical treatment by injection: lipopolysaccharide
|
Fig. 4
from Luo et al., 2019
|
whole organism il1b expression increased amount, abnormal
|
chemical treatment by injection: lipopolysaccharide
|
Fig. 4
from Luo et al., 2019
|
whole organism cxcl8b.1 expression increased amount, abnormal
|
chemical treatment by environment: double-stranded DNA
|
Fig. 1
from de Oliveira et al., 2015
|
whole organism cxcl8b.1 expression increased amount, abnormal
|
chemical treatment by environment: poly(I:C)
|
Fig. 1
from de Oliveira et al., 2015
|
whole organism cxcl8b.1 expression increased amount, abnormal
|
bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium
|
Fig. 1
from de Oliveira et al., 2015
|
whole organism cxcl8b.1 expression increased amount, abnormal
|
viral treatment by exposure to environment: Sprivirus cyprinus
|
Fig. 1
from de Oliveira et al., 2015
|
whole organism il1b expression increased amount, abnormal
|
bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium
|
Fig. 1
from Tyrkalska et al., 2016
|
whole organism neutrophil amount, normal
|
chemical treatment: tyrphostin AG 825
|
Figure 6
from Rahman et al., 2019
|
whole organism neutrophil amount, normal
|
chemical treatment: CP-724714
|
Figure 6
from Rahman et al., 2019
|
whole organism neutrophil amount, normal
|
transection: caudal fin, chemical treatment by environment: alvocidib
|
Fig. 2
from Hoodless et al., 2016
|
whole organism neutrophil amount, normal
|
transection: caudal fin, chemical treatment by injection: 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide
|
Fig. 2
from Hoodless et al., 2016
|
whole organism neutrophil normal amount, normal
|
high fat
|
Fig. 8
from Misselbeck et al., 2019
|
whole organism neutrophil normal amount, normal
|
high cholesterol
|
Fig. 8
from Misselbeck et al., 2019
|